Paclitaxel (PTX) can bind to
human serum albumin (HSA) via hydrophobic interaction, forming
Abraxane, which is a U.S. Food and Drug Administration (FDA) approved effective antitumor nanomedicine
drug. Herein, the effective
antitumor drug PTX is used to induce the self-assembly of HSA modified with either a
photosensitizer chlorin e6 (Ce6), which at the same time serves as a
chelating agent for Mn(2+) to enable magnetic resonance imaging, or acyclic
Arg-Gly-Asp (
cRGDyK) peptide that targets αvβ3-integrin overexpressed on
tumor angiogenic endothelium. Two types of
tumor-targeting
theranostic nanoparticles are constructed, either by coassembly of both HSA-Ce6 and HSA-RGD simultaneously or by forming an HSA-Ce6@HSA-RGD core-shell structure, with the assistance of PTX-induced
albumin aggregation. Such
albumin-based nanoparticles on one hand could targetαvβ3-integrin, as evidenced by both in vitro and in vivo experiments, and on the other hand enable combined photodynamic/
chemotherapy, which offers remarkably improved therapeutic efficacy to kill
cancer in comparison to the respective monotherapies. Our work presents a new type of
tumor-targeted multifunctional
albumin-based nanoparticles by
drug-induced self-assembly, which is a rather simple method without any sophisticated chemistry or materials engineering and is promising for multimodel imaging-guided combination
therapy of
cancer.